[go: up one dir, main page]

BR9609853A - Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer. - Google Patents

Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer.

Info

Publication number
BR9609853A
BR9609853A BR9609853-8A BR9609853A BR9609853A BR 9609853 A BR9609853 A BR 9609853A BR 9609853 A BR9609853 A BR 9609853A BR 9609853 A BR9609853 A BR 9609853A
Authority
BR
Brazil
Prior art keywords
structures
manifestation
cancer therapy
application
expression
Prior art date
Application number
BR9609853-8A
Other languages
English (en)
Inventor
Xiaomei Jin
Jack Roth
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR9609853A publication Critical patent/BR9609853A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ESTRUTURAS DE MANIFESTAçãO DE p16 E SUA APLICAçãO NA TERAPIA DO C‰NCER". Uma variedade de estruturas genéticas são reveladas e que encontrarão uso in vitro e in vivo na área da biologia tumoral e na terapia do câncer. Em particular, provê-se estruturas de manifestação que contêm uma região que codifica p16 e outros elementos reguladores necessários à manifestação de um transcrito de p16. Uma versão da estrutura de manifestação é um vetor adenoviral réplico-deficiente. Também se provê métodos para a transformação de linhas de células e para a inibição da proliferação de células cancerosas.
BR9609853-8A 1995-07-17 1996-07-17 Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer. BR9609853A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50288195A 1995-07-17 1995-07-17
PCT/US1996/011787 WO1997003635A2 (en) 1995-07-17 1996-07-17 p16 EXPRESSION CONSTRUCTS AND THEIR APPLICATION IN CANCER THERAPY

Publications (1)

Publication Number Publication Date
BR9609853A true BR9609853A (pt) 1999-10-13

Family

ID=23999797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609853-8A BR9609853A (pt) 1995-07-17 1996-07-17 Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer.

Country Status (15)

Country Link
US (1) US6251871B1 (pt)
EP (1) EP0839207A2 (pt)
JP (1) JPH11510380A (pt)
KR (1) KR19990029028A (pt)
CN (1) CN1203632A (pt)
AU (1) AU724324B2 (pt)
BR (1) BR9609853A (pt)
CA (1) CA2227193A1 (pt)
CZ (1) CZ15498A3 (pt)
HU (1) HUP9901908A3 (pt)
NO (1) NO980218L (pt)
NZ (1) NZ313828A (pt)
PL (1) PL324750A1 (pt)
SK (1) SK6598A3 (pt)
WO (1) WO1997003635A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US7163925B1 (en) * 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
EP0862445B2 (en) † 1995-10-06 2017-03-22 Arch Development Corporation Combination of herpes simplex virus and chemotherapy for treating cancer
JP2001524812A (ja) * 1997-02-20 2001-12-04 ヘパヴェック アクチエンゲゼルシャフト フール ジェンセラピー アポトーシス誘導タンパク質に対するｒｂの比率の減少による悪性細胞におけるアポトーシス細胞死の誘導方法
TR199902202T2 (xx) 1997-03-14 1999-12-21 Unilever N.V. Dondurulmu� g�da �r�n�.
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
KR19990086165A (ko) * 1998-05-26 1999-12-15 성재갑 Cdk４ 의 저해제인 p16의 카복시말단이 절단된 결손형cδp１６ 단백질, 그의 유전자
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US20040005294A1 (en) * 2002-02-25 2004-01-08 Ho-Young Lee IGFBP-3 in the diagnosis and treatment of cancer
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
AU2004293474B2 (en) 2003-11-24 2010-12-23 Canji, Inc. Reduction of dermal scarring
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
US7695965B2 (en) * 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
CN103293308B (zh) * 2013-05-24 2014-11-26 尉军 一种检测肿瘤标志物p16抗原表位氨基酸序列及应用
CN104558147B (zh) * 2015-01-20 2017-11-07 刘林林 一种检测宫颈癌标志物cdkn2a抗原表位多肽及应用
EP3295181A4 (en) 2015-05-14 2018-11-14 Expression Pathology, Inc. Srm/mrm assay for the fibroblast growth factor receptor 2 (fgfr2) protein
AU2016268215B2 (en) 2015-05-22 2019-10-31 Expression Pathology, Inc. SRM/MRM assay for the cyclin-dependent kinase inhibitor 2A (p16) protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
ATE242806T1 (de) 1992-10-16 2003-06-15 Cold Spring Harbor Lab Umlagerung des cyclin komlexes und seine darauf bezogenen anwendungen
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
MY119195A (en) * 1993-12-30 2005-04-30 Shell Int Research Lightweight, wide-bodied compliant tower.
AU685627B2 (en) 1994-03-18 1998-01-22 Myriad Genetics, Inc. Germline mutations in the MTS gene and method for detecting predisposition to cancer at the MTS gene
JPH08510651A (ja) 1994-03-18 1996-11-12 ミリアド・ジェネティックス・インコーポレイテッド Ｍｔｓ遺伝子、それにおける変異、およびｍｔｓ遺伝子配列を用いる癌の診断方法
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
KR970702915A (ko) 1994-04-29 1997-06-10 린다 버겐 종양 세포의 치료 감응성 향상 방법(Enhancing The Sensitivity of Tumor Cells to Therapies)
DE19501073A1 (de) * 1995-01-16 1996-08-01 Nova C O R D Ag Bildverarbeitungsverfahren zur Ermittlung der Strukturfestigkeit eines Prüfobjektes mit diffus streuender Oberfläche
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5672508A (en) 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
HUP0004326A3 (en) 1997-02-18 2003-07-28 Canji Inc San Diego Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Also Published As

Publication number Publication date
US6251871B1 (en) 2001-06-26
SK6598A3 (en) 1998-09-09
HUP9901908A2 (hu) 1999-09-28
WO1997003635A2 (en) 1997-02-06
NO980218L (no) 1998-03-16
JPH11510380A (ja) 1999-09-14
CZ15498A3 (cs) 1998-07-15
KR19990029028A (ko) 1999-04-15
CN1203632A (zh) 1998-12-30
CA2227193A1 (en) 1997-02-06
EP0839207A2 (en) 1998-05-06
AU724324B2 (en) 2000-09-14
WO1997003635A3 (en) 1997-05-15
PL324750A1 (en) 1998-06-08
NZ313828A (en) 1999-02-25
AU6647896A (en) 1997-02-18
NO980218D0 (no) 1998-01-16
HUP9901908A3 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
BR9609853A (pt) Estruturas com manifestação de p16 e sua aplicação na terapia de c‰ncer.
BR9809846A (pt) Método para produzir um adenovìrus deficiente em replicação
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
IS4762A (is) Samfallandi eitlaveiru genaferjukerfi og frumulínur
DE69634752D1 (de) Adenovirale vektoren beinhaltend ein prostata spezifisches antigen (psa) "response element"
FI970983L (fi) Molekyylien siirto solujen sytoplasmaan
BR0014087A (pt) Composições com pérolas de caroteno - xantofila estáveis e métodos de uso
DK0863984T3 (da) Fremgangsmåder og præparater til behandling af cancer
PT1034185E (pt) Composicoes farmaceuticas que contem a pentraxina longa ptx3
EP1007537A4 (en) RECEPTOR PROTEIN DESIGNATED BY 2F1
NO975557L (no) Immortalisering og dissimortalisering av celler
NO982874L (no) Farmasöytiske preparater med vitamin D-analoger
NO20012220L (no) Adenovirus-mediert genterapi
FI930050A0 (fi) Foerfarande foer finfoerdelning av konstmaterial eller organiska naturliga polymerer
AU7423391A (en) Dna constructs for the expression of proteins in the mammary gland of transgenetic mammals
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
PT952975E (pt) Compostos bi-aromaticos ligados por um radical hetero-etinileno e composicoes farmaceuticas e cosmeticas que os contem
DK1135169T3 (da) Anvendelse af et farmaceutisk præparat indeholdende et anticancermiddel og mindst et peptid.
AU6193699A (en) Antisense-sequences for inhibiting the expression of the adhesion molecule icam-1
BR0012704A (pt) Anticorpos antitumor, proteìnas e usos dos mesmos
BR9917238A (pt) Aplicador de revestimento lìquido tendo meios para aplicação espaçada
EP1023459A4 (en) DETERMINATION OF EXISTING QUANTITIES OF CYCLINE-DEPENDENT KINASE INHIBITOR P27 AS A PROGNOSTIC FACTOR IN CANCER PATIENTS
DK0870015T3 (da) Xylanaser, gener, der koder for disse, samt anvendelser deraf
IT1230167B (it) Procedimento per il rivestimento con pellicola di composizioni farmaceutiche con dispersioni di polimeri.

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal